Michael Lachman

OIS Index

Market Rebounds in November; OIS Index Does Not

The OIS Index of ophthalmic stocks declined by 2.3% in November on the heels of a 17.7% decline in October, failing to participate in the market rebound that lifted most stocks following the October sell-off. During November, the overall US stock market as measured by the Russell 3000 Index gained...

Read More
OIS Index

OIS Index Follows Stock Market Lower in October

The OIS Index of ophthalmic stocks declined by 17.7% during the October market correction, which saw a 7.5% decline in the overall US stock market as measured by the Russell 3000 Index. Healthcare stocks underperformed in October: the NASDAQ Biotechnology Index lost 14.6% of its value, and a composite of...

Read More
Small Cap Stocks Lead the Way for OIS Index in September

Small Cap Stocks Lead the Way for OIS Index in September

The OIS Index of ophthalmic stocks gave back some of its recent gains in September, declining by 4.1% against an overall flat market backdrop. The NASDAQ Biotechnology Index and the overall US stock market as measured by the Russell 3000 Index were essentially unchanged during the month, while a composite...

Read More
Glaukos and STAAR Drive OIS Index into Record Territory

Glaukos and STAAR Drive OIS Index into Record Territory

The OIS Index of ophthalmic stocks surged to new highs in August, driven by two of the highest-weighted stocks in the index. The OIS Index gained 16.3% in August, while the overall US stock market, as measured by the Russell 3000 Index gained 3.3%, the NASDAQ Biotechnology Index gained 4.8%,...

Read More
OIS Index

OIS Index Lags Market Benchmarks in July

The OIS Index of ophthalmic stocks declined by 1.1% in July, against a strong overall market backdrop. During the month, the overall US stock market as measured by the Russell 3000 Index gained 3.9%, while the NASDAQ Biotechnology Index gained 8.6% and a composite of US medical device stocks gained...

Read More
OIS Index

OIS Index Hits New Highs; Two New Companies Added

The OIS Index stayed in four-digit territory in June, finishing the month at 1,017 and again outperforming its stock market benchmarks. The OIS Index gained 2.1% during the month, while the NASDAQ Biotechnology Index declined by 0.9%; the overall US stock market, as measured by the Russell 3000 Index, declined...

Read More
OIS Index Breaks 1,000 as Rally in Ophthalmic Stocks Rolls On

OIS Index Breaks 1,000 as Rally in Ophthalmic Stocks Rolls On

The OIS Index returned to four-digit territory in May, surpassing 1,000 for the first time since the index was launched in October 2016. The OIS Index was initially set to 1,000 on October 1, 2016, and over the ensuing 20 months, US stocks have gained 30% in value and other...

Read More
Ophthalmic Stocks' Rally Rolls Through April

Ophthalmic Stocks’ Rally Rolls Through April

The OIS Index gained 5.2% in April, on the heels of a 4.4% gain in March. Ophthalmic stocks have far outperformed key market benchmarks over the past one and three months. The NASDAQ Biotechnology Index declined 3% in April, while the overall US stock market as measured by the Russell...

Read More
OIS Index

OIS Index Outperforms Market in Another Volatile Month

The OIS Index gained 4.4% in March, far outperforming its key benchmarks during another volatile month for the markets. The NASDAQ Biotechnology Index declined by 1.3% in March, while the overall US stock market as measured by the Russell 3000 Index declined by 2.2%. A composite of US medical device...

Read More
OIS Index Follows Market Downward During a Rocky February

OIS Index Follows Market Downward During a Rocky February

The OIS Index declined by 4.2% in February, tracking stock market benchmarks during a volatile month. The NASDAQ Biotechnology Index suffered a slightly larger decline of 5.4%, while a composite of US medical device stocks and the overall US stock market as measured by the Russell 3000 Index declined by...

Read More

OIS Index Delivers Small Gain, But Lags Benchmarks in January

In January, the OIS Index scratched out a small gain, but underperformed its relevant benchmarks. The OIS Index gained 0.3%, compared with gains of 7% for the NASDAQ Biotechnology Index, 10.2% for a composite of US medical device stocks, and 5.2% for the overall US stock market as measured by...

Read More

OIS Index Declines Despite Positive Milestone Achievements

December was a month of positive milestones for key companies in the OIS Index. On December 18, more than two months before its February 28 Prescription Drug User Fee Act (PDUFA) date, Aerie Pharmaceuticals announced Food and Drug Administration approval of Rhopressa (netarsudil ophthalmic solution 0.02%) for glaucoma and ocular...

Read More